Sort by
Refine Your Search
-
Listed
-
Employer
- ;
- University of Cambridge
- King's College London
- University of Oxford
- University of Sheffield
- Durham University
- University of Glasgow
- Cardiff University
- Loughborough University
- Nottingham Trent University
- Plymouth University
- University of Bath
- University of London
- University of Nottingham
- 4 more »
- « less
-
Field
-
), a Research Centre of the Natural Environment Research Council. You will be a key part of the NCAS@Cambridge group based in the Department of Chemistry at the University of Cambridge. The successful
-
Advert Biocurator / Senior Biocurator Division of Infection and Immunity School of Medicine College of Biomedical and Life Sciences The global lipid database, LIPID MAPS (http://lipidmaps.org/) is
-
Job id: 088725. Salary: £43,205 - £47,978 per annum, including London Weighting Allowance. Posted: 30 April 2024. Closing date: 15 May 2024. Business unit: Faculty of Life Sciences & Medicine
-
discipline and a PhD (or equivalent) in the field of Medicine, Pharmaceuticals, or related to vaccine technologies or drug delivery. You will have knowledge of vaccines and formulation strategies as
-
contract of 9 months is offered with the possibility of an extension. Essential requirement 1: candidates must have (or be about to obtain) a PhD in materials science, chemistry, or chemical engineering
-
be expected to have an undergraduate degree in pharmaceutical / medicinal chemistry or closely related discipline, and a PhD in pharmaceutical / medicinal chemistry or closely related discipline, and
-
based in our group at Cancer Research UK's Cambridge Institute (CI) and involves close collaboration with our group based in the University Chemistry Department. The post is available from Autumn 2024
-
essential that you hold a relevant PhD/Dphil in Chemistry or Medicinal Chemistry, together with significant research experience post PhD and relevant to the duties of the role. You will have records
-
cells. Work at this innovation stage is entirely in vitro. The project, funded by PCUK’s Research Innovation Fund, is a first step towards delivering precision medicine to target a metabolic vulnerability
-
cells. Work at this innovation stage is entirely in vitro. The project, funded by PCUK’s Research Innovation Fund, is a first step towards delivering precision medicine to target a metabolic vulnerability